Hepatic lipase (HL) and cholesteryl ester transfer protein (CETP) are key enzymes of plasma lipid/lipoprotein metabolism (1,2).
(SNPs) in the HL promoter have been discovered and are associated with reduced HL activity. These variant alleles are common, such that almost 40% of Caucasians are heterozygous or homozygous carriers (5) .
A common SNP for CETP has been extensively studied, which creates a TaqI restriction site. Although this SNP is located within intron 1, the TaqIB2 allele has been associated with reduced CETP activity. Strong linkage association with the CϪ629A CETP promoter polymorphism, which influences gene expression and CETP activity, may provide an explanation (6) . In this issue of the Journal, Blankenberg et al. (7) examine further the CϪ629A polymorphism and a linked structural-domain variant, I405V.
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Consistent intermediate (HDL) phenotype accompanies loss-of-function variants. Plasma HDL-C shows an inverse relationship with atherosclerosis in the general population, which may be explained (at least in part) by the role of HDL in mediating reverse cholesterol transport (RCT). Accordingly, HDL-C is widely used as a biomarker for coronary risk. As noted, several common HL and CETP variants have been associated with reduced enzymatic mass and activity (6,8 -15) . The HL gene accounts for one-fourth of genetic variation in HDL-C levels (16) . Both HL (5, 8, 10, 11, (17) (18) (19) (20) and CETP (7, (12) (13) (14) (21) (22) (23) (24) (25) (26) (27) loss-offunction variant carriers consistently have been associated with higher HDL-C levels (and higher apolipoprotein AI levels, when measured).
Inconsistent effect on clinical (disease) phenotype.
Despite the consistent impact of genetic variation in HL and CETP on lipids and lipoproteins, their effect on clinical phenotype is controversial (Table 1) . Hypothetically, if HDL-C is a surrogate for RCT, variant allele carriage should be antiatherogenic. Conversely, higher HDL 2 may signal reduced RCT flux due to reduced enzymatic function; in this case, allele carriage would be proatherogenic (5, 28) . Into this controversy step the studies of Andersen et al. (5) and Blankenberg et al. (7) .
CURRENT STUDIES
Andersen et al. (5) investigated an association between three SNPs in the HL promoter, levels of HDL-C, and risk of ischemic heart disease (IHD). A large (N ϭ 9,121) representative sample of Copenhagen residents was genotyped, of which 957 had IHD. To expand the disease population, 921 additional IHD patients were added. The three variant HL alleles were common (frequencies, 0.21 to 0.22) and tightly linked. Levels of HDL-C and apolipoprotein AI increased in a stepwise fashion from wild-type to triple heterozygous to triple homozygous status. Clinical IHD, defined as previous myocardial infarction (MI) and/or cardiologistdiagnosed angina pectoris, was more prevalent, with an odds ratio (OR) of 1.5 ([confidence interval] CI 1.0 to 2.2) for homozygotes (Ϸ5% of subjects) compared with wild-type subjects. Increased IHD prevalence persisted after adjustment for age, gender, and HDL-C (OR ϭ 1.4, CI 1.1 to 1.9). The impact of HL variant homozygosity on disease was amplified in the presence of the relatively atherogenic 43 apolipoprotein E genotype, the adjusted OR increasing to 2.0 (CI 1.2 to 3.2).
This "paradoxic" association with IHD despite higher HDL-C finds support in a recent German trial (28) . Among 200 men undergoing elective coronary angiography, Dugi et al. (28) found the presence of the Ϫ514T HL promoter variant to be strongly associated with lower HL activity (p Ͻ 0.001) and greater angiographic coronary artery disease (CAD) extent (p Ͻ 0.05). The association was accounted for mainly by patients with normal HDL-C levels (Ͼ37 mg/dl). This HDL-C "paradox" was attributed to loss of RCT functions dependent on HL, such as formation of nascent, pre-␤ HDL particles and HLenhanced uptake of cholesteryl ester from HDL by the hepatic SR-B1 receptor. Low-variant HL activity was proposed to be atherogenic primarily in the setting of normal HDL-C, whereas high-variant HL activity might be insufficient to compensate for reduced HDL with associated loss of the anti-inflammatory and antithrombotic properties.
Andersen et al. (5) also ascribe to this explanation: higher HDL-C associated with HL variants might mark reduced flux through the RCT system, whereas in most other contexts it reflects increased capacity. In further support, they draw an analogy to previous studies from Copenhagen (23) (and elsewhere [22] ) where CETP loss-of-function variants resulted in increased HDL-C but were associated with increased IHD risk.
In contrast to the antiatherogenic view of HL is an angiographic study of lipid-lowering in 49 men with mixed dyslipidemia (11) . Treated subjects with the wild-type genotype had the greatest decrease in HL activity, improvement in HDL 2 -C and LDL buoyancy, and angiographic regression. Given differing patient populations, study size and design, therapeutic interventions, and end points, the implications of this smaller study in the present context remain unclear (11) . However, these divergent results highlight the complexity of lipid/lipoprotein metabolism associated with HL and the dependence of clinical outcomes on both multiple interacting environmental (14) and genetic factors.
Blankenberg et al. (7) investigated associations among CETP CϪ629A and I405V polymorphisms, CETP activity, HDL-C, and the risk of fatal cardiovascular events. The study population included 1,211 German CAD patients in the AtheroGene study who were genotyped and prospectively followed for a median of four years, during which time 82 fatal cardiovascular events occurred. The two polymorphisms studied were found to be linked, with CϪ629A better explaining the outcomes. The variant Ϫ629A allele (38% prevalence) was associated with lower CETP activity (with an allele dosage effect) and higher HDL-C. Mortality, but not other cardiovascular outcomes, was substantially lower for carriers of one or two A alleles (4.6%, 4.0%) than for wild-type homozygotes (10.4%, p Ͻ 0.0001). Statin therapy was of benefit only in the high-risk CC (wild-type) patients, in whom it neutralized the genotype-associated hazard.
Given the tight linkage between the Ϫ629A and the TaqIB2 variant alleles (6, 15) , the Blankenberg et al. study (7) supports earlier observations from REGRESS, which found an effect of pravastatin on atherosclerosis progression only in B1B1 (homozygous wild-type) subjects (21) . The intermediate (1HDL-C, 2CETP) phenotype-bygenotype result also is consistent with several earlier studies. Mechanistically, it might be hypothesized that statins act by decreasing CETP activity and cholesteryl ester transport from protective HDL to atherogenic VLDL. However, differences in survival by genotype were shown to be independent of HDL-C, CETP activity, and clinical covariables (7). Statin therapy was not randomized, and change in lipids by genotype with therapy was not assessed. Hence, the mechanism of survival advantage is unclear.
The AtheroGene clinical result is in contrast to several other studies, that found either no relationship of genotype to IHD risk or an opposite association (higher risk, greater treatment benefit for variant allele carriers) (Table 1) (14, 22, 23, 27, 29) . Indeed, directionally different results for CETP I405V risk were reported from the neighboring Danish group (relative risk 1.4; CI 1.0 to 1.9 for women carriers of the 405V variant) (23) . Of course, the studies differ in design, including baseline disease, gender, HDL-C, and therapy. But the example is illustrative of the lack of a consistent correlation of CETP genotype with clinical outcome.
Brown et al. (2) proposed that apparently conflicting findings could be reconciled if CETP activity were either protective or harmful depending on the atherogenicity of the apoB particles receiving cholesteryl ester from HDL. Genetically increased CETP would be protective and reduced CETP atherogenic in populations at low cardiovascular risk (low LDL-C, high HDL-C) and with low CAD prevalence (22, 24) , whereas the reverse would occur in high-risk (high LDL-C, low HDL-C), high-CADprevalence groups. This hypothesis deserves further investigation, but it does not appear to reconcile all reported studies (7, 27, 29) .
DISCUSSION
The discovery of common genetic diversity within the human genome, including over four million SNPs (Ϸ1% functionally active), has raised the hope that there will be increased understanding of disease pathogenesis, improved individual risk prediction, and customized preventive and therapeutic measures (pharmacogenomics). This promise
has not yet been realized. The relation of high versus low levels of HL and CETP activity to HDL-C levels and overall risk is complex and likely situation-dependent. Accurate, readily measured markers of RCT flux are not available (HDL-C alone appears inadequate) but are certainly needed. Despite relatively consistent biomarker associations, inconsistent disease associations are a major impediment to the clinical application of genetic polymorphism determinations.
What might explain these discrepancies? Despite their promise, genetic association studies have been fraught with inconsistencies and failures of replication (30) . Proposed explanations include chance associations (or missed associations) in populations of small size, publication bias (toward positive studies), population stratification artifacts (and other design issues in the selection of cases and controls) (28) , imprecision in phenotyping and outcome assessment, and the use of SNPs themselves as genetic markers (31) .
Moreover, it appears unlikely that common genetic variants, allowed by natural selection to become highly prevalent, will have strong independent risk associations.
Rather, multiple interacting genetic and environmental factors (diet, exercise, drugs) likely will need to be accounted for to predict risk reliably. We recently proposed the concept of "genetic burden" (32) . Individual dysfunctional polymorphisms not associated individually with discernible excess risk might progressively increase aggregate risk if considered together. Redundancy within metabolic pathways might allow for compensation for deficiency in one enzyme, but a combination of deficiencies in a series of proteins in a critical pathway (e.g., among genes for RCT) could progressively overwhelm compensatory mechanisms.
Finally, it recently has been proposed that "haplotype blocks" rather than individual SNPs may be the preferred unit of genetic risk. The SNPs do not occur in random combinations but in a relatively few fixed patterns within variably sized domains of deoxyribonucleic acid ("haplotype blocks") delimited by hot spots of meiotic recombination (33) . Determining the net effect on disease risk of all co-inherited genetic polymorphisms within a haplotype block is an appealing avenue for clinical investigation.
In summary, the studies of Andersen et al. (5) and Blankenberg et al. (7) highlight the potential of HL and CETP polymorphisms to influence coronary heart disease (CHD) risk in carefully defined populations. However, taken together (Table 1) (34, 35) association studies continue to defy simple characterization, and before clinical application can be considered, many questions still must be answered. Certainly, a need for replication exists, including prospective studies in very large and well-defined populations (with Ͼ500 to 1,000 events). Interventions (e.g., with statin therapy) should be randomized by genotype. Genetic and environmental modifiers should be carefully controlled. Combinations of polymorphisms in multiple genes in critical pathways ("genetic burden") should be assessed, and haplotypes (not just SNPs) should be evaluated. With
